---
id: 050
title: D-Test for Inducible Clindamycin Resistance
category: antimicrobials
subcategory: clindamycin
tags: [clindamycin, D-test, MLSB-resistance, erm-genes, MRSA]
difficulty: hard
---

## Question

What is the **D-test**, and why is it critical for detecting inducible clindamycin resistance in *S. aureus*? Use the **"D-Zone Disappears"** mnemonic.

## Answer

### **"D-Zone Disappears" Mnemonic:**

**D-shaped zone of inhibition appears:**
- **D**etects inducible resistance
- **Z**one flattens near erythromycin disc
- **O**ccurs with erm genes (*ermA*, *ermB*, *ermC*)
- **N**o clindamycin should be used if positive
- **E**xposure to macrolide induces resistance

**Disappears = Positive D-test = Do NOT use clindamycin**

### **What is the D-Test?**

**Test Setup:**
- Place **erythromycin disc** (inducer) and **clindamycin disc** (target)
- Distance: **15-26 mm edge-to-edge** apart
- Standard culture plate with *S. aureus*

**Interpretation:**

| D-Test Result | Appearance | Phenotype | Clindamycin Use? |
|---------------|------------|-----------|------------------|
| **Positive ("D-shape")** | Zone of inhibition around clindamycin **flattens** near erythromycin disc | **iMLSB** (inducible MLSB) | **❌ NO** (will fail) |
| **Negative (round)** | Zone around clindamycin remains **circular** | MS phenotype (macrolide resistance, clinda sensitive) | ✅ YES (safe to use) |
| **Constitutive resistance** | **No zone** around clindamycin | cMLSB (constitutive MLSB) | **❌ NO** (resistant) |

### **Mechanism of Inducible Resistance:**

**Genetic Basis:**
- **erm genes** (*ermA*, *ermB*, *ermC*) encode ribosomal methylases
- Most common: ***ermC* (35%)**, *ermA* (20%)

**Induction Process:**
1. Macrolide (erythromycin) exposure → activates *erm* gene transcription
2. Methylation of **23S rRNA** at A2058 position (50S ribosome)
3. Prevents binding of **MLSB antibiotics** (Macrolides, Lincosamides, Streptogramin B)
4. **Cross-resistance** to clindamycin develops during therapy

**Clinical Problem:**
- Isolate appears **clindamycin-susceptible** on standard testing
- During treatment → erythromycin (from prior exposure or co-infection) induces resistance
- **Treatment failure** occurs

### **When to Perform D-Test:**

**CLSI Guidelines:** Perform D-test on *S. aureus* isolates that are:
- **Erythromycin-resistant** AND
- **Clindamycin-susceptible** (by standard disc diffusion)

### **Prevalence:**

| Population | iMLSB Prevalence | Notes |
|------------|------------------|-------|
| **MRSA** | 15-76% | Higher in hospital-acquired MRSA |
| **MSSA** | 4-20% | Lower than MRSA |
| **CA-MRSA (USA)** | ~10% | Regional variation |

## Key Points

### **Clinical Decision-Making:**

**D-test POSITIVE (iMLSB phenotype):**
- **Do NOT use clindamycin** (high failure risk)
- Use alternative: Vancomycin, daptomycin, linezolid

**D-test NEGATIVE (MS phenotype):**
- **Safe to use clindamycin**
- Macrolide resistance due to efflux (*mef* genes), NOT *erm* genes

**Constitutive MLSB (cMLSB):**
- Resistant to both erythromycin AND clindamycin on standard testing
- No D-test needed (already resistant)

### **Three Phenotypes Summary:**

| Phenotype | Ery | Clinda | D-Test | Mechanism | Use Clinda? |
|-----------|-----|--------|--------|-----------|-------------|
| **MS** | R | S | Negative | *mef* (efflux) | ✅ YES |
| **iMLSB** | R | S | **Positive** | *erm* (inducible) | **❌ NO** |
| **cMLSB** | R | R | N/A | *erm* (constitutive) | **❌ NO** |

### **Clinical Pearls:**
- **Always request D-test** for MRSA if erythro-R, clinda-S
- iMLSB more common in **HA-MRSA** than CA-MRSA
- Treatment failure occurs in **~20-30%** of iMLSB cases if clindamycin used
- **MLSB resistance = cross-resistance** to macrolides, lincosamides (clindamycin), streptogramin B

## Sources

- [PMC4411429: Inducible Clindamycin Resistance in S. aureus]
- [PMC7787115: D-Test and Erm Genes in MRSA]
- [PMC3118052: Inducible Clindamycin Resistance Clinical Samples]
- [CLSI Guidelines: D-Test Performance Standards]

## Media

N/A
